Amgen/百济神州注射用贝林妥欧单抗启动II期临床 适应症为急性淋巴细胞白血病

新浪财经
Oct 24

药物临床试验登记与信息公示平台数据显示,Amgen Inc./百济神州(北京)生物科技有限公司的一项在复发或难治性B细胞前体急性淋巴细胞白血病(R/R B-ALL)和微小残留病变阳性(MRD+)B-ALL成人和青少年患者中研究贝林妥欧单抗皮下给药的安全性、有效性和药代动力学的1/2期开放性研究已启动。临床试验登记号为CTR20254217,首次公示信息日期为2025年10月24日。该药物剂型为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10